We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+52.18%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$649M
AUM Growth
+$162M
Cap. Flow
+$16.8M
Cap. Flow %
2.6%
Top 10 Hldgs %
48.42%
Holding
76
New
11
Increased
16
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$31.6M
2
ALKS icon
Alkermes
ALKS
+$17.8M
3
ARDX icon
Ardelyx
ARDX
+$15.4M
4
RGLS
Regulus Therapeutics
RGLS
+$13.3M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.1M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$63.8M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$16.1M
3
ARWR icon
Arrowhead Research
ARWR
+$13.3M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$10.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 81.14%
2 Miscellaneous 18.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
$7.27M 1.12%
250,000
+100,000
+67% +$1.79M
HRTX icon
27
Heron Therapeutics
HRTX
$60.3M
$7.04M 1.09%
700,000
– –
NKTR icon
28
Nektar Therapeutics
NKTR
$2.3B
$6.97M 1.08%
30,000
– –
TLPH icon
29
Talphera
TLPH
$61.8M
$6.73M 1.04%
50,000
– –
ADXS
30
DELISTED
Advaxis Inc
ADXS
$6.72M 1.04%
55,967
+32,634
+140% +$1.83M
APTO
31
DELISTED
Aptose Biosciences, Inc.
APTO
$6.4M 0.99%
+2,407
New +$7.24M
EGRX
32
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$6.2M 0.96%
400,000
– –
CBPO
33
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$6.05M 0.93%
90,000
-5,000
-5% -$310K
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$1.27B
$5.27M 0.81%
120,000
– –
ASPX
35
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$5.25M 0.81%
100,000
– –
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$4.73M 0.73%
1,000,000
– –
ARAV
37
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.49M 0.69%
33,333
– –
IMDZ
38
DELISTED
Immune Design Corp.
IMDZ
$4.31M 0.66%
140,000
-60,000
-30% -$1.67M
NSTG
39
DELISTED
NanoString Technologies, Inc.
NSTG
$4.18M 0.64%
300,000
– –
RMTI icon
40
Rockwell Medical
RMTI
$31.4M
$4.11M 0.63%
3,636
– –
BMY icon
41
CALL
Bristol-Myers Squibb
BMY
$130B
$3.7M 0.57%
5,000
– –
CHRS icon
42
Coherus Oncology
CHRS
$188M
$3.63M 0.56%
+222,200
New +$3.13M
DERM
43
DELISTED
Dermira, Inc.
DERM
$3.62M 0.56%
+200,000
New +$3.34M
ADVM
44
DELISTED
Adverum Biotechnologies
ADVM
$3.51M 0.54%
6,500
– –
CBIO
45
Crescent Biopharma
CBIO
$638M
$3.4M 0.52%
4,723
– –
DRNA
46
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.29M 0.51%
+200,000
New +$2.31M
AGEN
47
Agenus
AGEN
$326M
$3.18M 0.49%
40,760
+7,642
+23% +$470K
FWP
48
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.13M 0.48%
+21,429
New +$3.09M
DARE icon
49
Dare Bioscience
DARE
$14.3M
$2.8M 0.43%
3,750
– –
GNVC
50
DELISTED
GenVec, Inc.
GNVC
$2.77M 0.43%
132,930
– –
1
2
3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Cormorant Asset Management held 76 positions worth $649M, up 33% from $486M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management's Q4 2014 filing shows 11 new, 16 increased, 10 reduced and 6 closed positions. Its largest new stake was Celgene Corp: 300,000 shares worth $33.6M. The largest sale was Puma Biotechnology, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q4 2014 buy was Celgene Corp: 300,000 shares worth $33.6M.
  • Cormorant Asset Management added most to Alkermes in Q4 2014, an estimated $17.8M increase.
  • Cormorant Asset Management's biggest Q4 2014 reduction was Puma Biotechnology, cutting an estimated $63.8M.
  • Cormorant Asset Management fully exited Jazz Pharmaceuticals in Q4 2014, selling an estimated $16.1M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $649M portfolio in Q4 2014.
  • Cormorant Asset Management opened 11 new positions and closed 6 in Q4 2014.
  • Cormorant Asset Management's portfolio value rose 33% quarter-over-quarter to $649M.

Based on Cormorant Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.